Transaction · 0001468308-26-000028

Andrade Robert

Andrade Robert, CFO, reported an open-market or private sale at FENNEC PHARMACEUTICALS INC. involving 75000.000000 shares for an estimated $883500.00. Reported holdings after the transaction were 217675.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCFO
FENCFENNEC PHARMACEUTICALS INC.
Filing timeAug 28
Trade dateAug 27, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
…
Pre-filing
…
Returns since
…

FENC price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
FENC since 2026-08-28Filed 6 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001468308-26-000028
Common shares
Transaction date
Aug 27, 2026
Filed Aug 28, 2026, 09:42 PM · 1d delay
Shares
75.0k sh
$1.17k per share
Estimated value
-$88.3M
Computed from shares × price
Holdings after
217k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Large Holdings Reduction 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHIEF FINANCIAL OFFICER

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2026, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). A port…

  2. F2

    Shares acquired through the exercise of an option contract with exercise price of $5.10 and an expiration date of June 27, 2027.

Original filing · 0001468308-26-000028
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

FENC